Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.5266
-0.1670 (-24.12%)
Inactive · Last trade price on Dec 2, 2024

Company Description

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.

The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation.

Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Oncternal Therapeutics, Inc.
Oncternal Therapeutics logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees30
CEOJames Breitmeyer

Contact Details

Address:
12230 El Camino Real, Suite 230
San Diego, California 92130
United States
Phone858 434 1113
Websiteoncternal.com

Stock Details

Ticker SymbolONCT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001260990
CUSIP Number68236P107
ISIN NumberUS68236P2065
Employer ID62-1715807
SIC Code2834

Key Executives

NamePosition
Dr. James B. Breitmeyer M.D., Ph.D.President, Chief Executive Officer and Director
Richard G. Vincent CPAChief Financial Officer and Treasurer
Dr. Rajesh Krishnan Ph.D.Chief Technical and Scientific Officer
Chase C. Leavitt J.D.General Counsel and Secretary
Pablo UrbanejaSenior Vice President of Corporate Development

Latest SEC Filings

DateTypeTitle
Nov 25, 20248-KCurrent Report
Nov 14, 20248-KCurrent Report
Nov 6, 202410-QQuarterly Report
Oct 15, 2024144Filing
Sep 12, 20248-KCurrent Report
Aug 8, 202410-QQuarterly Report
Aug 8, 20248-KCurrent Report
Jun 21, 20248-KCurrent Report
May 9, 202410-QQuarterly Report
May 9, 20248-KCurrent Report